Effects of a Supervised Training Program on Functional Capacity in Patients With HFpEF and Chronotropic Incompetence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-18

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 12 weeks. Patients with heart failure with preserved ejection fraction, functional class NYHA II-III, and chronotropic incompetence criteria will be enrolled. A sample size estimation \[alfa: 0.05, power: 80%, a 15% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SD±2)\] of 80 patients (20 per arm) would be necessary to test our hypothesis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of a Supervised Training Program on Functional Capacity in Patients With HF and Cardiorenal Syndrome

NCT06640140

Heart Failure Cardiorenal Syndrome

NOT_YET_RECRUITING NA

Effects of an Exercise Program in Women Over 60 yr. With HFpEF and Sarcopenia on Functional Capacity and Quality of Life

NCT06655532

Heart Failure With Preserved Ejection Fraction (HFpEF) Sarcopenia Women

NOT_YET_RECRUITING NA

Exercise-based Cardiac Rehabilitation Program on Hospitalized Heart Failure Patients Submitted to Cardiac Transplantation

NCT03506737

Heart Failure Transplant; Failure, Heart Physical Activity

UNKNOWN NA

Effects of a Home-based Exercise Program on Functional Capacity and Quality of Life in Heart Failure Patients

NCT03615157

Chronic Heart Failure

UNKNOWN NA

3/7 Resistance Training Method in Cardiac Rehabilitation

NCT05696990

Heart Failure Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent clinical entity that predominantly affects women \>60 years old, whose incidence has increased in the last decade and has a complex and multifactorial pathophysiology. Chronotropic incompetence (CrI) has emerged as a crucial mechanism, particularly in patients older than 60 years, and is associated with more significant functional impairment. Supervised training programs in patients with heart failure and reduced ejection fraction and CrI have improved functional capacity and chronotropic response. However, we do not have evidence about the effects of a supervised training program on patients with HFpEF and CrI. This work aims to evaluate the effect of a supervised exercise program for 12 weeks in patients with HFpEF and CrI on peak oxygen consumption (peakVO2) and chronotropic response.

This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 12 weeks. Patients with HFpEF, functional class NYHA II-III, and CrI criteria will be enrolled. A sample size estimation \[alfa: 0.05, power: 80%, a 15% loss rate, and at least a delta change of mean peakVO2: +2,4 mL/kg/min (SD±2)\] of 80 patients (20 per arm) would be necessary to test our hypothesis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Preserved Ejection Fraction Chronotropic Incompetence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Blinded only for the evaluator of primary and secondary endpoints

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual care

Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training.

Group Type NO_INTERVENTION

No interventions assigned to this group

Supervised aerobic training

Patients allocated to this arm will receive the usual care plus supervised aerobic training

Group Type ACTIVE_COMPARATOR

Supervised aerobic training

Intervention Type BEHAVIORAL

Supervised moderate to high-intensity interval aerobic training

Supervised aerobic plus low to moderate-intensity strenght training

Patients allocated to this arm will receive the usual care plus supervised aerobic and low to moderate-intensity strength training

Group Type ACTIVE_COMPARATOR

Supervised aerobic training

Intervention Type BEHAVIORAL

Supervised moderate to high-intensity interval aerobic training

Supervised aerobic plus low to moderate-intensity strength training

Intervention Type BEHAVIORAL

Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training

Supervised aerobic plus moderate to high-intensity strenght training

Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training.

Group Type ACTIVE_COMPARATOR

Supervised aerobic training

Intervention Type BEHAVIORAL

Supervised moderate to high-intensity interval aerobic training

Supervised aerobic plus moderate to high-intensity strength training

Intervention Type BEHAVIORAL

Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supervised aerobic training

Supervised moderate to high-intensity interval aerobic training

Intervention Type BEHAVIORAL

Supervised aerobic plus low to moderate-intensity strength training

Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training

Intervention Type BEHAVIORAL

Supervised aerobic plus moderate to high-intensity strength training

Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with heart failure with preserved ejection fraction according to 2021 ESC guidelines for Heart Failure.
* N-terminal pro-B-type natriuretic peptide (NT-proBNP) \>125 pg/mL in the last month
* Stable symptomatic heart failure patients (New York Heart Association functional class II-III/IV) during the last month
* Age ≥ 60 years old.
* Blunted heart rate (HR) response during a maximal cardiopulmonary exercise testing (CPET), defined as a chronotropic index \<0.62 if previous treatment with Beta-blockers or chronotropic index \<0.80 in patients without beta-blockers. Chronotropic index= \[HRpeak exercise - HRrest\] / \[220 - age - HRrest\]

Exclusion Criteria

* Inability to perform a valid baseline cardiopulmonary exercise test
* Cardiac pacemaker
* Significant primary moderate-to-severe valve disease
* Effort angina or signs of ischemia during CPET
* Primary cardiomyopathies
* Cardiac transplantation
* Any other comorbidity with a life expectancy of less than one year

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No